Bio-Rad Laboratories (BIO) revenue breakdown
By segment, Clinical Diagnostics is the largest at 60% of fiscal 2025 revenue; Life Science grew fastest, 4% a year over 9 years.
By region, UNITED STATES is the largest at 40% of fiscal 2025 revenue, growing 3% a year over 9 years.
Revenue by segment
Fiscal years, as Bio-Rad Laboratories reports them in its 10-K filings; fiscal 2025 total $2.6B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Diagnostics | $1.3B | $1.4B | $1.4B | $1.4B | $1.3B | $1.5B | $1.5B | $1.5B | $1.5B | $1.6B | 60% |
| Life Science | $731M | $785M | $862M | $886M | $1.2B | $1.4B | $1.3B | $1.2B | $1.0B | $1.0B | 40% |
| All Other Segments | $14M | $14M | $16M | $14M | $9M | $6M | $4M | $4M | $500,000 | — | — |
Revenue by region
Fiscal years, as Bio-Rad Laboratories reports them in its 10-K filings; fiscal 2025 total $2.6B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $771M | $800M | $864M | $899M | $1.0B | $1.1B | $1.2B | $1.1B | $1.0B | $1.0B | 40% |
| Europe | $742M | $758M | $792M | $770M | $858M | $947M | $852M | $820M | $834M | $882M | 34% |
| Asia | $427M | $461M | $496M | $505M | $546M | $688M | $639M | $563M | $522M | $513M | 20% |
| Other (primarily Canada and Latin America) | $128M | $140M | $138M | $137M | $137M | $157M | $155M | $166M | $169M | $165M | 6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BIO.
Open BIO in InvestinglyQuestions
Where does Bio-Rad Laboratories make its money?
In fiscal 2025, by segment: Clinical Diagnostics $1.6B, Life Science $1.0B.
From Bio-Rad Laboratories's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.